Typically ulcerative colitis manifests in young adults (15-40 years of age) and is more prevalent in males but the onset of disease after age of 50 is also common 1,3,5. A combination of environmental and genetic factors are thought to play a role in the pathogenesis, although the condition remains idiopathic.
Ulcerative colitis is less prevalent in smokers than in non-smokers.
Clinically patients have chronic diarrhoea (sometimes bloody) associated with tenesmus, pain and fever 1. C-reactive protein levels are usually normal 6.
Unlike Crohn disease which is characteristically a transmural disease, ulcerative colitis is usually limited to the mucosa and submucosa 5. Chronic disease is associated with a significantly elevated malignancy risk, of up to 0.5-1.0% per year after 10 years of disease.
The diagnosis is often made with endoscopy, which also allows biopsy of any suspicious areas.
- primary sclerosing cholangitis (PSC)
- moya moya phenomenon
- ankylosing spondylitis
- colorectal carcinoma
- thoracic manifestations of ulcerative colitis
- uveitis and iritis
- erythema nodosum and pyoderma gangrenosum
- thrombotic complications
- fatty liver
- seronegative spondyloarthropathy
- chronic active hepatitis 7
Involvement of the rectum is almost always present (95%) 1, with the disease involving variable amounts of the most proximal colon, in continuity. The entire colon may be involved, in which case oedema of the terminal ileum may also be present (so-called backwash ileitis).
In very severe cases, the colon becomes atonic, with marked dilatation, worsened by bacterial overgrowth. This leads to toxic megacolon which although uncommon has a poor prognosis.
Non-specific findings, but may show evidence of mural thickening (more common), with thumbprinting also seen in more severe cases.
Double contrast barium enema allows for exquisite detail of the colonic mucosa and also allows the bowel proximal to strictures to be assessed. It is however contraindicated if acute severe colitis is present due to the risk of perforation.
Mucosal inflammation leads a granular appearance to the surface of the bowel. As inflammation increases, the bowel wall and haustra thicken.
In chronic cases, the bowel becomes featureless with the loss of normal haustral markings, luminal narrowing and bowel shortening (lead pipe sign).
Small islands of residual mucosa can grow into thin worm-like structures (so-called filiform polyps)
Colorectal carcinoma in the setting of ulcerative colitis is more frequently sessile and may appear to be a simple stricture.
CT will reflect the same changes that are seen with a barium enema, with the additional advantage of being able to directly visualise the colonic wall, the terminal ileum and identify extra-colonic complications, such as perforation or abscess formation. It is important to note however that CT is insensitive to early mucosal disease 2.
Inflammatory pseudopolyps may be seen if large enough, in well distended bowel. In areas of mucosal denudation, abnormal thinning of the bowel may also be evident 2.
A cross section of the inflamed and thickened bowel has a target appearance due concentric rings of varying attenuation, also known as mural stratification 1-2.
In chronic cases, fat submucosal deposition is seen particularly in the rectum (fat halo sign). Also in this region, extramural deposition of fat, leads to thickening of the perirectal fat, and widening of the presacral space 1,2.
Strictures are also common and are not all malignant. These are predominantly due to marked muscularis mucosa hypertrophy, which is also in part responsible for the lead pipe sign.
Colorectal carcinoma is often sessile. Focal loss of mural stratification or excessive mural thickness (1.5 cm) should prompt endoscopic evaluation 2.
The current status of MRI in ulcerative colitis is that of a promising, non-invasive technique for imaging extent of more severe disease.
The most striking abnormalities in ulcerative colitis are wall thickening and increased enhancement.
The median wall thickness in ulcerative colitis ranges from 4.7 to 9.8 mm. In general, the more severe the inflammation, the thicker the colonic wall. A colonic wall thickness <3 mm is usually considered as normal, 3-4 mm as a "gray zone," and >4 mm as pathological.
Enhancement of the mucosa with absent or decreased enhancement of the submucosa produces a low SI stripe - the so-called submucosal stripe.
Other features are the loss of haustral markings, backwash ileitis, mild enhancement and no wall thickening, and there is increased SI of the pericolonic fat noted.
Treatment and prognosis
Total colectomy is curative of both the intestinal symptoms and of the potential risk of colorectal carcinoma. Medical therapy is able in some cases to control the colonic disease but does not remove the need to carefully and regularly screen for malignancy.
Due to close surveillance patients with ulcerative colitis have a normal or even slightly improved survival compared to normal population 3. This is clearly not the case if the disease is not diagnosed or treatment not available.
10-15% of cases initially presenting as ulcerative colitis later progress to Crohn disease.
- 1. Roggeveen MJ, Tismenetsky M, Shapiro R. Best cases from the AFIP: Ulcerative colitis. Radiographics. 26 (3): 947-51. doi:10.1148/rg.263055149 - Pubmed citation
- 2. Gore RM, Balthazar EJ, Ghahremani GG et-al. CT features of ulcerative colitis and Crohn's disease. AJR Am J Roentgenol. 1996;167 (1): 3-15. AJR Am J Roentgenol (citation) - Pubmed citation
- 3. Loftus EV, Silverstein MD, Sandborn WJ et-al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46 (3): 336-43. Gut (link) - Free text at pubmed - Pubmed citation
- 4. Thoeni RF, Cello JP. CT imaging of colitis. Radiology. 2006;240 (3): 623-38. Radiology (full text) - doi:10.1148/radiol.2403050818 - Pubmed citation
- 5. Kumar V, Abbas AK, Fausto N et-al. Robbins & Cotran Pathologic Basis of Disease. Elsevier Health Sciences. (2009) ISBN:1437720153. Read it at Google Books - Find it at Amazon
- 6. Mark B. Pepys, Gideon M. Hirschfield. C-reactive protein: a critical update. (2003) The Journal of Clinical Investigation. 111 (12): 1805. doi:10.1172/JCI18921 - Pubmed
- 7. Wolfgang Dähnert. Radiology Review Manual. (2011) ISBN: 9781609139438